Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

Colin C Pritchard, Colm Morrissey, Akash Kumar, Xiaotun Zhang, Christina Smith, Ilsa Coleman, Stephen J Salipante, Jennifer Milbank, Ming Yu, William M Grady, Jonathan F Tait, Eva Corey, Robert L Vessella, Tom Walsh, Jay Shendure, Peter S Nelson, Colin C Pritchard, Colm Morrissey, Akash Kumar, Xiaotun Zhang, Christina Smith, Ilsa Coleman, Stephen J Salipante, Jennifer Milbank, Ming Yu, William M Grady, Jonathan F Tait, Eva Corey, Robert L Vessella, Tom Walsh, Jay Shendure, Peter S Nelson

Abstract

A hypermutated subtype of advanced prostate cancer was recently described, but prevalence and mechanisms have not been well-characterized. Here we find that 12% (7 of 60) of advanced prostate cancers are hypermutated, and that all hypermutated cancers have mismatch repair gene mutations and microsatellite instability (MSI). Mutations are frequently complex MSH2 or MSH6 structural rearrangements rather than MLH1 epigenetic silencing. Our findings identify parallels and differences in the mechanisms of hypermutation in prostate cancer compared with other MSI-associated cancers.

Figures

Figure 1. MSH2 and MSH6 rearrangements are…
Figure 1. MSH2 and MSH6 rearrangements are associated with loss of protein expression and MSI.
(a) Four of seven hypermutated cases had complex rearrangements in MSH2 and MSH6 or both genes. Shown is a representative complex MSH2 rearrangement present in hypermutated cases LuCaP 147 and 05–165 (LuCaP 147 was derived from autopsy patient 05–165). Breakpoints were confirmed by Sanger sequencing. Genomic coordinates are hg19. Detail on additional structural rearrangements and other mismatch repair gene mutations is provided in Tables 1 and 2 and Supplementary Figs 2–9. (b) Hypermutated tumors exhibited microsatellite instability by PCR. Shown is representative data for LuCaP 58, which is positive for MSI in 3/5 mononucleotide marker systems (MONO-27, BAT-25 and NR-24, arrows). All hypermutated tumors tested were MSI-PCR positive in at least 2/5 loci (Supplementary Data 1). (c) Hypermutated tumors LuCaP 58, 73 and 147 have loss of MSH2 and MSH6 proteins by IHC. Similar results were observed in hypermutated tumors from rapid autopsy patients (Supplementary Fig. 11). A representative non-hypermutated tumour (LuCaP 23.1) has intact expression. LuCaP 145 had mono-allelic mutations in MSH2 and MSH6 but was not hypermutated. IHC shows loss of MSH6 protein expression in some tumour cells. Scale bars, 0.1 mm.

References

    1. Kumar A. et al.. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl Acad. Sci. USA 108, 17087–17092 (2011).
    1. Barbieri C. E. et al.. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).
    1. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
    1. Kandoth C. et al.. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
    1. Pritchard C. C. et al.. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J. Mol. Diagn. 14, 357–366 (2012).
    1. Walsh T. et al.. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl Acad. Sci. USA 107, 12629–12633 (2010).
    1. Pritchard C. C. et al.. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 16, 56–67 (2014).
    1. Jarzen J., Diamanduros A. & Scarpinato K. D. Mismatch repair proteins in recurrent prostate cancer. Adv. Clin. Chem. 60, 65–84 (2013).
    1. Burger M. et al.. Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur. Urol. 50, 770–775 (2006).
    1. Chen Y. et al.. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 61, 4112–4121 (2001).
    1. Velasco A. et al.. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 94, 690–699 (2002).
    1. Sun X., Chen C., Vessella R. L. & Dong J. T. Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate 66, 660–666 (2006).
    1. Chen Y. et al.. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int. J. Oncol. 22, 1033–1043 (2003).
    1. Dahiya R. et al.. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int. J. Cancer 72, 762–767 (1997).
    1. Watanabe M. et al.. Microsatellite instability in human prostate cancer. Br. J. Cancer 72, 562–564 (1995).
    1. Baca S. C. et al.. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).
    1. White N. M., Feng F. Y. & Maher C. A. Recurrent rearrangements in prostate cancer: causes and therapeutic potential. Curr. Drug Targets 14, 450–459 (2013).
    1. Wu D., Zhang C., Shen Y., Nephew K. P. & Wang Q. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol. Metab. 22, 474–480 (2011).
    1. Petko Z. et al.. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 11, 1203–1209 (2005).
    1. O'Roak B. J. et al.. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat. Genet. 43, 585–589 (2011).
    1. Pritchard C. C. et al.. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 16, 56–67 (2014).
    1. Salipante S. J., Scroggins S. M., Hampel H. L., Turner E. H. & Pritchard C. C. Microsatellite instability detection by next-generation sequencing. Clin. Chem. 24987110 (2014).

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe